The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even companies that have no revenue, no profit, and a record of falling short, can manage ...
(MENAFN- GlobeNewsWire - Nasdaq) Company to present 40-week topline results from the Phase 2 study of migaldendranib (MGB), a first-in-class subcutaneous nanomedicine, being developed for the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback